Summary
Rivaroxaban was noninferior to warfarin in preventing all-cause stroke and noncentral nervous system embolism in patients with atrial fibrillation, according to new findings from the Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF].
- Arrhythmias
- Cerebrovascular Disease Clinical Trials
- Cerebrovascular Disease
- © 2010 MD Conference Express
Tools
ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, with Lower Bleeding Risk
Permalink:
Table of contents
Cited By...
- No citing articles found.